Visiongain has launched a new pharma report C-Reactive Protein (CRP) Test Market Report 2020-2030: Prospects by Assay Type (Immunoturbidimetric Assay, ELISA (Clinical, Non-Clinical), Chemiluminescence Immunoassay (CLIA), Others), Detection Range (High Sensitivity C-reactive Protein, Conventional CRP, Cardiac CRP (cCRP)), Disease Area (Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus, Others), End-User (Global C-reactive Protein Testing Market: End Use Movement Analysis, Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home, Others), and Geography.

The global C-Reactive Protein (CRP) Test market is anticipated to surpass USD 2.5 billion by 2030.

C-reactive protein testing is used to detect inflammation following surgery, immune system disease (Lupus), rheumatoid arthritis, cancer, inflammatory bowel disease (IBD), and cardiovascular disease (CVD). There is a high incidence of cardiovascular diseases such as heart attacks & strokes, and these tests are important for predicting the occurrence of such diseases.

ELISA, Chemiluminescence immunoassay (CLIA), High-sensitivity C-reactive protein (hsCRP) assay, and Immunoturbidimetric Assays are the immunoassays used for C-reactive protein testing. The high-sensitivity C-reactive protein (hsCRP) assay is used as a marker for heart risk assessment & as a tool for heart disease prognosis. The American Heart Association & the Centers for Disease Control and Prevention recommends hsCRP as a sensitive assay to predict vascular disease compared with more traditional C-reactive protein levels assays.

It is also anticipated that strong government policies would boost growth over the forecast period. Also, it is projected that the recent development of paper-based diagnostic devices will drive the market further. For clinical diagnosis of C-reactive protein in patients, these instruments are compact and easy to use.

The chronic inflammation is a key contributing factor for several chronic diseases, such as lupus, rheumatoid arthritis (RA), ulcerative colitis, and Crohn's disease among others. According to the Arthritis Foundation, there are approximately Roughly 1.5 million people are affected by rheumatoid arthritis in the United States, which is anticipated to boost the growth of the CRP test market over the forecast period.

Furthermore, CRP has several applications for the development of potential new compounds for inflammatory diseases within in vitro & in vivo. Consequently, the growing prevalence of inflammatory diseases is anticipated to boost market growth further.

Increased government efforts are expected to drive growth over the forecast period to improve primary healthcare settings and enhance their infrastructure. The government across geographies is playing a crucial role in guiding general physicians to use point-of-care CRP testing devices for the rapid detection of infectious disease in primary health care settings. These activities are expected to drive the growth in subsequent years of C-reactive protein testing tools.

Over the forecast period, immunoturbidimetric assay is anticipated to grow with the highest CAGR owing to growing research & development expenditure & increased market availability of C-reactive protein testing products. Therefore, for specific protein assays such as CRP, immunoturbidimetric tests are increasingly approved.

North America dominated the global CRP test market owing to the presence of major players in the region, advancement in technology, & well-established healthcare infrastructure. The market is anticipated to expand further over the forecast period due to growing government expenditure on healthcare facilities, and growing awareness among people about research and testing tools in healthcare.

However, the Asia Pacific CRP test market is anticipated to grow with the highest CAGR over the forecast period owing to emerging economies like Japan, China & India coupled with growing research & development expenditure from private & public entities. In addition, government support & partnerships among various pharma & biotech companies are anticipated to offer fresh revenue generation avenues for the companies operating in this region.

Some of the major players operating in this industry are Abaxis, Inc., Abbott, ABCAM PLC, Beckman Coulter, INC., Boditech Med, INC., Danaher, Demeditec Diagnostics GMBH, F Hoffmann-La Roche Ltd., Getein Biotech, Inc., Horiba Ltd., LabCorp, Merck & Co., Inc., Orion Diagnostica Oy, Ortho Clinical Diagnostics, Quest Diagnostics, R&D Systems, INC., Randox Laboratories Ltd., Siemens Healthineers, Thermo Fisher Scientific, Inc., Uni-smart among other prominent players.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.